Athenex, Inc., a biopharmaceutical company based in Buffalo, New York, is making waves in the world of cancer treatment. The company's focus is on the discovery, development, and commercialization of drugs to combat the disease, operating through its Oncology Innovation Platform and Commercial Platform segments. Athenex's Orascovery product candidates, including Oral paclitaxel and encequidar, show promise in the treatment of metastatic breast cancer. Tirbanibulin ointments, part of the company's Src Kinase product candidates, are targeted at actinic keratosis, skin cancers, and psoriasis. Athenex is also developing KUR-501, an autologous product to treat children with relapsed-refractory high risk neuroblastoma, as well as KUR-502, an allogeneic product aimed at treating adults with CD19 positive malignancies. The company also has a robust pipeline, including KUR-503, an allogeneic product currently in preclinical development for advanced hepatocellular carcinoma. In addition, Athenex is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome p450 3A enzymes within the gastrointestinal tract. Finally, the company has a portfolio of TCRs that recognize hotspot mutations in p53, KRAS, and EGFR genes for multiple tumors. Athenex was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015, and has been making waves in the cancer treatment space ever since.